Falk M et al. Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy. Curr Oncol 2023; Jan 30;30(2):1692-1698. doi: 10.3390/curroncol30020130
Jori B et al. Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy. Current Oncol 2022; Sep 16;29(9):6628-6634. doi: 10.3390/curroncol29090520
Jori B et al. Comparison of Resistance Spectra After First and Second Line Osimertinib Treatment Detected by Liquid Biopsy. Cancers 2021; Jun 8;13(12):2861. doi: 10.3390/cancers13122861.
Lipinski S und Tiemann K. Extracellular Vesicles and Their Role in the Spatial and Temporal Expansion of Tumor–Immune Interactions. Int J Mol Sci 2021; Apr; 22(7): 3374. doi: 10.3390/ijms22073374
Keppens C et al. Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe. J Mol Diagn 2018; Jul;20(4):483-494. DOI: 10.1016/j.jmoldx.2018.03.006
Müller J et al. Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens. J Thorac Oncol 2017; Oct;12(10):1503-1511. doi: 10.1016/j.jtho.2017.07.014
Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non-Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy. J Thorac Oncol 2017; Nov;12(11):e186-e188. doi: 10.1016/j.jtho.2017.07.018